

Treats traumatic brain injuries (TBI)

Reduces system-wide side effects

Crosses the bloodbrain barrier

NEED FOR CereTRec

- Very stable product, does not require a cold chain, and is capable of being administered in multiple Point-Of-Care settings- from a hospital, to battlefield clinics
- CereTRec can additionally be utilized as a platform for the delivery of other compounds, opening the door for licensing deals with other pharmaceutical companies

CHROMOLOGIC ADVANTAGE

- BAID is the first SAAS product on the market to optimize for mobile identification and EMR integration from the start
- Each unique hash from user's biometric data remains HIPPA compliant

MARKET OPPORTUNITY

- At \$600 per treatment, we can achieve blockbuster status with over \$1BB in sales annually
- With the conservative assumption that drug development companies spend 2% of their research budget toward CRO's, we believe we can create revenue streams of \$120MM annually

